Median Technologies Raises €40M to Scale AI-Powered Lung Cancer Screening

Event summary

  • Median Technologies launches €40M capital increase, with potential upsize to €50M, to fund U.S. and European deployment of eyonis® LCS.
  • Company has secured €30M in backstop commitments from Lion Point Capital and other guarantors.
  • eyonis® LCS received FDA 510(k) clearance in February 2026, positioning it for commercial rollout in the U.S.
  • European CE marking decision for eyonis® LCS expected in the coming weeks.
  • Proceeds will also support development of additional AI-based Software as Medical Devices within the eyonis® portfolio.

The big picture

Median Technologies' capital raise underscores the strategic importance of AI in early cancer diagnosis, particularly in lung cancer screening. The company is positioning itself at the intersection of AI, medical imaging, and early detection, aiming to shift healthcare systems from reactive to proactive cancer management. With a clear regulatory pathway in the U.S. and growing momentum in Europe, the funding will enable Median to capitalize on a multi-billion-dollar opportunity in pan-cancer early diagnostics.

What we're watching

Market Penetration
How quickly Median Technologies can scale eyonis® LCS adoption in the U.S. and Europe, given the large addressable markets.
Regulatory Approval
Whether the anticipated CE marking for eyonis® LCS will be granted and its impact on European market entry.
Portfolio Expansion
The pace at which Median Technologies can develop and commercialize additional AI-based SaMDs within the eyonis® portfolio.

Related topics

Technology